1.Edlinger, M, Baumgartner, S, Eltanaihi-Furtmüller, N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs. 2005; 19(1): 27–42.
2.Buckley, PF, Correll, CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008; 69(Suppl 1): 4–17.
3.Nyhuis, AW, Faries, DE, Ascher-Svanum, H, et al. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010; 10:75.
4.Newcomer, JW, Weiden, PJ, Buchanan, RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry. 2013; 74(11): 1108–1120.
5.Correll, CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006; 67(1): 160–161.
6.Correll, CU. Switching and combining antipsychotics. CNS Spectr. 2010; 15(4 Suppl 6): 8–11.
7.Kane, JM, Leucht, S, Carpenter, D, Docherty, JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003; 64(Suppl 12): 5–19.
8.Correll, CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010; 25(Suppl 2): S12–S21.
9.Takeuchi, H, Thiyanavadivel, S, Agid, O, Remington, G. Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: a meta-analysis. Schizophr Res. 2017; 189: 4–8.
10.Maeda, K, Sugino, H, Akazawa, H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin–dopamine activity modulator. J Pharmacol Exp Ther. 2014; 350(3): 589–604.
11.Correll, CU, Skuban, A, Ouyang, J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015; 172(9): 870–880.
12.Kane, JM, Skuban, A, Ouyang, J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015; 164(1–3): 127–135.
13.Fleischhacker, WW, Hobart, M, Ouyang, J, et al. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomised, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2017; 20(1): 11–21.
14.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision, Washington, DC: American Psychiatric Association; 2000.
16.Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
17.Guy, W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health; 1976.
18.Peuskens, J. Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol. 2000; 15(Suppl 4): S15–S19.
19.Correll, CU, Citrome, L, Haddad, PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016; 77(Suppl 3): 1–24.
20.de Smidt, C, Haffmans, J, Hoencamp, E. Antipsychotics switching strategies in real life. A longitudinal study in clinical practice. Eur J Psychiat. 2012; 26(1): 41–49.
21.Casey, DE, Carson, WH, Saha, AR, et al., Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003; 166(4): 391–399.
22.Takeuchi, H, Kantor, N, Uchida, H, et al. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophr Bull. 2017; 43(4): 862–871.
23.Takeuchi, H, Thiyanavadivel, S, Agid, O, Remington, G. Rapid vs. slow antipsychotic initiation in schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2018; 193:29–36.